Kieffer Lynn Tara's most recent trade in Enanta Pharmaceuticals Inc was a trade of 7,500 Common Stock done . Disclosure was reported to the exchange on Feb. 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Chief Product Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 7,500 | 36,805 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Chief Product Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.59 per share. | 12 Feb 2025 | 3,326 | 33,479 (0%) | 0% | 5.6 | 18,592 | Common Stock |
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Chief Product Strategy Officer | Sale of securities on an exchange or to another person at price $ 8.06 per share. | 06 Dec 2024 | 2,283 | 29,305 (0%) | 0% | 8.1 | 18,401 | Common Stock |
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Chief Product Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.60 per share. | 01 Dec 2024 | 753 | 31,588 (0%) | 0% | 8.6 | 6,476 | Common Stock |
| Enanta Pharmaceuticals Inc | Lynn Tara Kieffer | Chief Product Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2024 | 81,000 | 81,000 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Chief Product Strategy Officer | Sale of securities on an exchange or to another person at price $ 12.33 per share. | 17 Jun 2024 | 7,266 | 32,341 (0%) | 0% | 12.3 | 89,590 | Common Stock |
| Enanta Pharmaceuticals Inc | Kieffer Lynn Tara | Chief Product Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 3,320 | 40,580 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Kieffer Tara Lynn | Chief Product Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.41 per share. | 12 Feb 2024 | 973 | 39,607 (0%) | 0% | 12.4 | 12,075 | Common Stock |
| Enanta Pharmaceuticals Inc | Lynn Tara Kieffer | Sr. VP, New Prod. Strat. & Dev | Sale of securities on an exchange or to another person at price $ 9.63 per share. | 05 Dec 2023 | 2,125 | 37,260 (0%) | 0% | 9.6 | 20,464 | Common Stock |
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Sr. VP, New Prod. Strat. & Dev | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.49 per share. | 01 Dec 2023 | 753 | 39,385 (0%) | 0% | 9.5 | 7,146 | Common Stock |
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Sr. VP, New Prod. Strat. & Dev | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2023 | 83,000 | 83,000 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Sr. VP, New Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 11,747 | 46,863 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Sr. VP, New Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 9,250 | 35,116 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Sr. VP, New Product Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.77 per share. | 13 Feb 2023 | 6,725 | 40,138 (0%) | 0% | 52.8 | 354,878 | Common Stock |
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Sr. VP, New Product Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.33 per share. | 01 Dec 2022 | 498 | 25,866 (0%) | 0% | 44.3 | 22,076 | Common Stock |
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Sr. VP, New Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Sr. VP, New Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 18,500 | 26,364 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Sr. VP, New Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 1,289 | 8,416 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Sr. VP, New Product Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.49 per share. | 14 Feb 2022 | 552 | 7,864 (0%) | 0% | 62.5 | 34,494 | Common Stock |
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Sr. VP, New Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 327 | 7,127 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Sr. VP, New Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 28,400 | 28,400 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Sr. VP, New Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 6,800 | 6,800 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Tara Lynn Kieffer | Sr. VP, New Product Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2020 | 65,000 | 65,000 | - | - | Stock Option (right to buy) |